检索范围:
排序: 展示方式:
Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives
Felicitas THOL, Arnold GANSER
《医学前沿(英文)》 2010年 第4卷 第4期 页码 356-362 doi: 10.1007/s11684-010-0220-5
null
《医学前沿(英文)》 2011年 第5卷 第1期 页码 45-52 doi: 10.1007/s11684-011-0117-y
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.
关键词: acute promyelocytic leukemia arsenic all-trans retinoic acid survival
FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches
《医学前沿(英文)》 2022年 第16卷 第6期 页码 896-908 doi: 10.1007/s11684-022-0944-z
关键词: acute myeloid leukemia FGF13 prognosis immune-related genes bone marrow niches
《医学前沿(英文)》 2023年 第17卷 第3期 页码 518-526 doi: 10.1007/s11684-022-0958-6
关键词: acute lymphoblastic leukemia child venous thromboembolism epidemiology clinical characteristic risk factor
《医学前沿(英文)》 2022年 第16卷 第4期 页码 627-636 doi: 10.1007/s11684-020-0815-4
关键词: RUNX1 gene mutation acute myeloid leukemia transcriptional repression DNA methylation
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
《医学前沿(英文)》 2012年 第6卷 第4期 页码 416-420 doi: 10.1007/s11684-012-0224-4
Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL). In children, T-ALL usually has a worse prognosis than B-ALL, although childhood T-ALL prognoses have improved remarkably. The varying outcomes among T-ALL cases suggest that an unrecognized biological heterogeneity may contribute to chemo-resistance. Deep exploration of T-lymphocyte development in recent years has found a subgroup of patients with a phenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any other form of T-ALL. This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Flow cytometry data from T-ALL patients enrolled in Shanghai Children’s Medical Center between July 2002 and October 2010 were assessed according to Dr. Campana’s protocol. Among total 89 T-ALL cases, 74 cases had enough immunophenotype data available to differentiate between ETP (CD1a-, CD8-, CD5dim, at least one marker of stem cell or myeloid lineage) and non-ETP. From these 74 subjects, 12 ETP-ALL cases (16.2%) were identified. The event-free survival (EFS) rate at 66.8 months was 11.1%±10.1% for ETP-ALL and 57.6%±5.6% for non-ETP-ALL (P=0.003). The overall survival rates were 13.3%±11.0% for ETP-ALL and 64.7%±6.3% for non-ETP-ALL (P=0.002). Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic leukemia with poor prognosis.
关键词: acute lymphoblastic leukemia early T precursor prognosis
《医学前沿(英文)》 2022年 第16卷 第6期 页码 909-918 doi: 10.1007/s11684-021-0890-1
关键词: acute promyelocytic leukemia intracranial hemorrhage cytokines biomarker
《医学前沿(英文)》 2023年 第17卷 第4期 页码 685-698 doi: 10.1007/s11684-022-0942-1
关键词: acute myeloid leukemia acyl-CoA synthetase long chain family member 5 Wnt3a palmitoylation ABT-199
《医学前沿(英文)》 2022年 第16卷 第1期 页码 139-149 doi: 10.1007/s11684-021-0835-8
关键词: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
《医学前沿(英文)》 2021年 第15卷 第5期 页码 728-739 doi: 10.1007/s11684-021-0833-x
关键词: second hematopoietic stem cell transplantation acute leukemia relapse chemotherapy modified donor lymphocyte infusion
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia
《医学前沿(英文)》 2022年 第16卷 第3期 页码 442-458 doi: 10.1007/s11684-021-0877-y
关键词: T-cell acute lymphoblastic leukemia HDAC inhibitor chidamide NOTCH1 MYC ubiquitination
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia
null
《医学前沿(英文)》 2015年 第9卷 第1期 页码 1-9 doi: 10.1007/s11684-015-0381-3
With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvement in the treatment outcome and quality of life of patients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cell genetic lesions that are amendable to available target therapy, and optimizing treatment based on host pharmacodynamics and pharmacogenomics. Deeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemia such as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic alterations that have diagnostic, prognostic, or therapeutic implications. In this regard, several novel fusion transcripts are responsive to ABL tyrosine kinase inhibitors and potentially to JAK inhibitors. Genome-wide analyses have also unraveled the role of inherited cancer predisposing genes and small nucleotide polymorphisms of several genes in the development of childhood ALL. These advances promise to lead to more sophisticated personalized treatment strategies in the near future.
关键词: pharmacogenomics acute lymphoblastic leukemia genomics pharmacogenetics
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
null
《医学前沿(英文)》 2012年 第6卷 第3期 页码 248-262 doi: 10.1007/s11684-012-0206-6
The AML1-ETO fusion transcription factor is generated by the t(8;21) translocation, which is present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid leukemia (AML) patients. Both human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis in the absence of secondary events. In this review, we discuss the pathogenetic insights that have been gained from identifying the various events that can cooperate with AML1-ETO to induce AML in vivo. We also discuss potential therapeutic strategies for t(8;21) positive AML that involve targeting the fusion protein itself, the proteins that bind to it, or the genes that it regulates. Recently published studies suggest that a targeted therapy for t(8;21) positive AML is feasible and may be coming sometime soon.
关键词: AML1-ETO mouse model leukemia t(8 21) pathway hits mutation hematopoiesis Kasumi-1 CD34+
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
《医学前沿(英文)》 2020年 第14卷 第6期 页码 689-700 doi: 10.1007/s11684-020-0759-8
关键词: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
Current treatment strategy of acute promyelocytic leukemia
Jianqing Mi
《医学前沿(英文)》 2011年 第5卷 第4期 页码 341-347 doi: 10.1007/s11684-011-0169-z
关键词:
acute promyelocytic leukemia
all-
标题 作者 时间 类型 操作
Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives
Felicitas THOL, Arnold GANSER
期刊论文
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research
null
期刊论文
Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese
期刊论文
expression pattern of mutations coordinated by target repression and promoter hypermethylation in acutemyeloid leukemia
期刊论文
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
期刊论文
Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocyticleukemia
期刊论文
ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/-catenin signaling
期刊论文
comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acutelymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
期刊论文
unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acuteleukemia post-chemotherapy plus modified donor lymphocyte infusion
期刊论文
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
null
期刊论文